Ipratropium Bromide May Increase Risk For Cardiovascular Events
Patients taking ipratropium bromide, an anticholinergic used in the treatment of COPD, may be at an increased risk for cardiovascular events (CVE), including heart failure. Researchers from the University of Washington in Seattle, WA, and Hines VA Hospital in Hines, IL, conducted a cohort study on 82,717 US veterans with a new diagnosis of COPD [...]



